Ofatumumab with iphosphamide, etoposide and cytarabine for patients with transplantation-ineligible relapsed and refractory diffuse large B-cell lymphoma.

Br J Haematol · 2022 · PMC9322457 · PMID 35362096

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

highly significantno p-value reported

In the multivariate analysis, ECOG performance status, number of prior salvage therapies and time from the last therapy were statistically highly significant factors predictive of PFS and EFS ( Table S4 ).

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.